Microbes and asthma: Opportunities for intervention - 04/03/16
, Pieter S. Hiemstra, PhD b, Clarissa Prazeres da Costa, MD, PhD c, Markus Ege, MPH d, Michael Edwards, PhD e, Holger Garn, PhD f, Peter H. Howarth, MD g, Tuomas Jartti, MD h, Esther C. de Jong, PhD i, Rick M. Maizels, PhD j, Ben J. Marsland, PhD k, Henry J. McSorley, PhD j, Anne Müller, PhD l, Petra I. Pfefferle, PhD m, Huub Savelkoul, PhD n, Jürgen Schwarze, MD o, Wendy W.J. Unger, PhD p, Erika von Mutius, MD, MSc d, Maria Yazdanbakhsh, PhD a, Christian Taube, MD, PhD bAbstract |
The worldwide incidence and prevalence of asthma continues to increase. Asthma is now understood as an umbrella term for different phenotypes or endotypes, which arise through different pathophysiologic pathways. Understanding the many factors contributing to development of the disease is important for the identification of novel therapeutic targets for the treatment of certain asthma phenotypes. The hygiene hypothesis has been formulated to explain the increasing prevalence of allergic disease, including asthma. This hypothesis postulates that decreased exposure at a young age to certain infectious agents as a result of improved hygiene, increased antibiotic use and vaccination, and changes in lifestyle and dietary habits is associated with changes in the immune system, which predispose subjects to allergy. Many microbes, during their coevolution with human subjects, developed mechanisms to manipulate the human immune system and to increase their chances of survival. Improving models of asthma, as well as choosing adequate end points in clinical trials, will lead to a more complete understanding of the underlying mechanisms, thus providing an opportunity to devise primary and secondary interventions at the same time as identifying new molecular targets for treatment. This article reports the discussion and conclusion of a workshop under the auspices of the Netherlands Lung Foundation to extend our understanding of how modulation of the immune system by bacterial, parasitic, and viral infections might affect the development of asthma and to map out future lines of investigation.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : Hygiene hypothesis, asthma, sensitization, microbes, microbiome, helminths, viruses, immune regulation
Abbreviations used : DC, RSV, TLR, Treg
Plan
| Disclosure of potential conflict of interest: H. H. Smits has received grants and travel support from the Dutch Lung Foundation. P. S. Hiemstra has received travel support from Lung Foundation Netherlands and grants from Boehringer Ingelheim and Galapagos. C. Prazeres da Costa has received travel support from Longfonds, Netherlands. M. Ege has received grants from the German Federal Ministry of Research (BMBF), the German Research Foundation (DFG), the European Commission, the European Research Council, and Friesland Campina and has received royalties from Protectimmun GmbH. M. Edwards is a grant reviewer for NMRC Singapore; has consultant arrangements with Chiesi; is employed by GlaxoSmithKline; has received grants from GlaxoSmithKline, Chiesi, Merck, and Pfizer; has received payment for lectures from Pfizer; and has received travel support from the European Academy of Allergy and Clinical Immunology, the European Respiratory Society, and the American Academy of Allergy, Asthma & Immunology. H. Garn has received a grant from the German Research Foundation (DFG; SFB/TR22) and has received travel support from Lung Foundation Netherlands. T. Jartti has received a grant from the Academy of Finland. E. C. de Jong is employed by AMC, University of Amsterdam. R. M. Maizels is employed by the University of Edinburgh and has received grants from Wellcome Trust and the Rainin Foundation. B. Marsland has received travel support from the Netherlands Lung Foundation. H. J. McSorley has received a grant from Asthma UK. J. Schwarze has received travel support from the Netherlands Lung Foundation; has consultant arrangements with MEDA, GlaxoSmithKline, and Bausch & Lomb; is employed by the University of Edinburgh; has received grants from the Medical Research Council and the Wellcome Trust; has received payment for lectures from Abbvie and Thermo Fisher; and has received support for allergy study days for clinicians from Thermo Fisher Scientific, MEDA Pharmaceuticals, Nutritia, Mead Johnson Nutrition, GlaxoSmithKline, Abbott, IMed-Emerade, Allergy Therapeutics, and Stallergenes. E. von Mutius has received grants from European Research Council, the German Research Foundation, and FrieslandCampina; is on the Editorial Board for the New England Journal of Medicine; has served as an Associate Editor for the Journal of Allergy and Clinical Immunology; has provided expert testimony for the European Research Council and European Commission, UK Research Excellence Framework, AUKCAR, Messerli Research Institute, and University of Tampere; and has received payment for lectures from Novartis, Mundipharma, DOC Congress SRL, Oekosoziales Forum Oberoesterreich. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 3
P. 690-697 - mars 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
